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Abstract
Background
Flavonoids are a group of phenolic secondary plant metabolites that are ubiquitous in plant-
based diets. Data from anthropological, observational and intervention studies have shown
that many flavonoids are bioactive. For this reason, there is an increasing interest in investi-
gating the potential health effects of these compounds. The translation of these findings into
the context of the health of the general public requires detailed information on habitual die-
tary intake. However, only limited data are currently available for European populations.
Objective
The objective of this study is to determine the habitual intake and main sources of anthocya-
nidins, flavanols, flavanones, flavones, flavonols, proanthocyanidins, theaflavins and thear-
ubigins in the European Union.
Design
We use food consumption data from the European Food Safety Authority (EFSA) and the
FLAVIOLA Food Composition Database to estimate intake of flavonoids.
Results
Mean (±SEM) intake of total flavonoids in Europe was 428±49 mg/d, of which 136±14 mg/d
were monomeric compounds. Gallated flavan-3-ols (53±12 mg/d) were the main contribu-
tor. The lowest flavonoid intake was observed in Mediterranean countries (monomeric com-
pounds: 95±11 mg/d). The distribution of intake was skewed in many countries, especially
in Germany (monomeric flavonoids; mean intake: 181 mg/d; median intake: 3 mg/d).
Conclusions
The habitual intake of flavonoids in Europe is below the amounts found to have a significant
health effect.
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Introduction
Flavonoids are a group of secondary plant metabolites, derived from 2-phenylchroman, which
are ubiquitous in seed plants (spermatophytes) and therefore found in most plant-based foods
[1]. They exist both in monomeric (e.g. flavanols or anthocyanidins), and in polymeric form
(e.g. proanthocyanidins, theaflavins and thearubigins). Flavonoids have a wide range of biolog-
ical function in plants [2], such as the protection from UV radiation and as signalling mole-
cules for interaction with microbes [3]. Flavonoid-containing plants have also a long history of
medicinal use: for example the catechin-monomer rich extract of Acacia, catechu, has been de-
scribed as astringent in European pharmacopoeias since almost 400 years [4], and has also
been recommended to treat heart diseases [5]. In the 20th century, flavonoids were briefly con-
sidered to be a vitamin affecting capillary permeability [6], although it emerged quickly that
these compounds are not an essential dietary factor [7]. However, based on these observations,
flavonoid-containing drugs have been used extensively not only to treat disorders of the pe-
ripheral circulation, but also to treat radiation poisoning, intoxications and liver diseases [8].
In recent decades, there has been increasing interest in the potential beneficial effect of ha-
bitual flavonoid consumption on human health. Data from anthropological research [9] and
observational studies [10, 11] suggested that they can reduce the risk of cardio-vascular diseases
(CVD) although results from more recent studies have been less clear [12–15]. Due to their
ability to scavenge free radicals in vitro they have often been described as antioxidants although
it has been shown that this is an unlikely explanation for their activity in vivo [16]. A recent
meta-analysis of observational epidemiological studies suggested an overall beneficial effect of
flavonoid intake [17], however, the data available are more ambiguous. McCullough et al. find
the main beneficial effect emerge when comparing very low intake with low intake [13] and
this can be observed in other studies [12, 14]. While this could be explained by a threshold ef-
fect, there are also alternative explanations such as differences in dietary composition [15] or
other unknown confounding factors. It is therefore not possible to attribute the observed effect
to flavonoid intake alone. There are also no consistent associations between flavonoid intake
and cancer risk. A recent meta-analysis showed no beneficial association between flavonoid in-
take and breast cancer risk [18] or gastric cancers [19], while there was a beneficial effect with
smoking-related lung cancer [20] although only in some populations [21]. As with cardiovas-
cular diseases, the main beneficial effect is often found when comparing very low with low in-
takes [22]. This is in marked contrast to results from a recent study investigating associations
between flavonoid intake and the risk of type 2 diabetes in the EPIC cohort [23]: in this study,
higher intake is associated with lower risk at least for some compounds, and the analyses show
statistically significant trends.
While considerable attention has been focused on the beneficial health effects of flavonoids,
excessive intake can also result in significant adverse effects [24], however there is a paucity of
data on safety. Adverse affects range from mild gastro-intestinal symptoms to severe condi-
tions such as haemolytic anaemia. Although flavonoids have been used as hepatoprotective
drugs, flavonoids—and in particular gallated compounds found in green tea [25]—have been
associated with increased risk of hepatotoxicity [24]. Flavonoid consumption has also been
linked to haemolytic anaemia, and while this is best documented for (+)-catechin containing
drugs [8], it is documented for other flavonoids as well [26, 27]. Flavonoids can also interact
with cell proliferation by inhibiting topoisomerase 2 [28] and this can have both, a pro- and an
anti-carcinogenic effect; some epidemiological data suggest an increased risk of leukaemia in
neonates following high intake of bioflavonoids by mothers [29, 30]. Furthermore, the exten-
sive hepatic metabolism of flavonoids can result in extensive flavonoid-drug interactions, espe-
cially as flavonoids can induce and inhibit cytochrome P450 enzymes [31].
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There is an increased interest in exploring the benefits of establishing dietary recommenda-
tion for bioactives such as flavonoids [32], but there are still insufficient data on efficacy and
safety for most compounds. Although dietary intervention studies have been conducted to in-
vestigate the beneficial effect of flavonoids on health, most notably with flavan-3-ols [33], the
lack of standardised protocols and well defined intervention vehicles makes it often difficult to
interpret the results.
The development of dietary recommendations and also the interpretation of results from in-
tervention studies, requires reliable information on habitual flavonoid intake in the general
public. This information is also important to assess the potential health impact of these com-
pounds. However, there is a paucity of data available. While the flavonoid consumption data of
the European Prospective Investigation into Cancer (EPIC) provides detailed information on
flavonoid intake in this cohort [34], the data are not representative of the European public be-
cause of selection bias. Previously, we have used a novel food composition database, in combi-
nation with food consumption data from the European Food Safety Authority (EFSA), to
determine flavan-3-ol intake in the European Union [35]. We have now used the same meth-
ods and data to investigate the habitual consumption of selected monomeric and polymeric fla-
vonoids (see Fig 1 for a summary of the monomeric compounds included in this study) in the
adult population of the European Union.
Subjects and Methods
We have used the methods described previously [35] to determine mean and median intake of
flavonoids, using the 2011 EFSA Comprehensive European Food Consumption Database. This
database contains food consumption data for adults aged 18–64 years from 21 surveys
(~30,000 individuals) and 14 countries [36]. Information concerning the methodologies used
in each survey is presented in Table 1. Food consumption statistics are reported in g/day and
for habitual consumption. For each country, consumption data are given according to the 1st
(20 categories) and 2nd (140 categories) level of the FoodEx system and for the total population
[37]. The hierarchical food classification system ‘FoodEx’, developed by EFSA, was used to cod-
ify all food items. Food intake by non-consumers is reported as 0.
In order to estimate the flavonoid intake in Europe, we expanded the FLAVIOLA Flavanol
Food Composition database which contains food composition data for approximately 3,000
food items as described previously [35]. This database is based on the US Department of Agri-
culture database for the Flavonoid Content of Selected Foods [38], and the proanthocyanidins
(PA) Content of Selected Foods [39], expanded with values from Phenol-Explorer, a compre-
hensive database on the polyphenol content of foods [40]. These databases are the most up-to-
date databases on flavonoids and polyphenols, and include information for 500, 205, and 456
food items for flavonoids [38], PA [39] and polyphenols [40], respectively. We expanded and
completed the FLAVIOLA Flavanol Food Composition database using food data underlying
DINER (Data Into Nutrients for Epidemiological Research), a data-entry system for food rec-
ords created for EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk
[41]. This database was used for the calculation of the estimated flavonoid content of ~2,500
food items (82% of the 3000 total foods), using approximately 800 recipes. Retention and cook-
ing factors for approximately 500 food items were used to estimate the effect of processing (e.g.
frying, boiling, roasting, etc.) [42–44]. When information on the ingredients of commercial
food products was provided by manufacturers, their flavonoid content was also calculated;
where no information was available, products were matched to similar ones if possible. Food
items thought not to contain significant levels of flavanols (fish, meat and eggs) were treated as
logical zeros and omitted from the database. Dietary intake was estimated for the following
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major flavonoid subgroups (see also Fig 1 and Table 2): flavan-3-ol monomers
((–)-epicatechin, (–)-epicatechin-3-gallate, (–)-epigallocatechin. (–)-epigallocatechin-3-gallate,
(+)-catechin, (+)-gallocatechin, (+)-catechin-3-gallate, (+)-gallocatechin-3-gallate), theaflavins
(theaflavin, thearubigins, theaflavin-3,3'-digallate, theaflavin-3'-gallate, theaflavin-3-gallate),
Fig 1. Structures of monomeric flavonoids assessed in this study.
doi:10.1371/journal.pone.0128132.g001
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proanthocyanidins [PA] (dimers, trimers, 4-6mers, 7-10mers,>10mers), anthocyanidins (cya-
nidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin), flavones (apigenin, luteolin),
flavonols (isorhamnetin, quercetin, myricetin, kaempferol) and flavanones (hesperetin, narin-
genin, eriodictyol). Isoflavonoids, a subgroup of flavonoids with oestrogenic activity [45], are
not included in this study.
We present estimated mean and median values of flavonoid intake in mg/d. Further tables
are based on mean intake values to allow for comparison with other studies. The European
countries represented in the EFSA comprehensive database were grouped in regions to allow
for observations in each distinctive area (South: Italy, Spain, France; Central: Belgium, Czech
Republic, Germany, Hungary, Ireland, Latvia, Netherlands, UK; North: Denmark, Finland,
Sweden). Unless indicated otherwise, all data are given as the mean daily intake of the
respective flavonoid.
Availability of data
The flavonoid consumption data used in this study is available as S1 File: Flavonoid intake in
adults in the European Union by country and individual food.
Data processing and data analysis
The data available do not allow any statistical analyses, for example a comparison between dif-
ferent countries. Means shown are not weighted. Data analyses were conducted with R 3.1
[46].
Results
Overall intake
Data on flavonoid intake in adults was available for fourteen European countries, based on sur-
veys of more than 30,000 participants (Table 1). All studies were conducted between 1999 and
2005. Table 3 and Fig 2 show a summary of the mean and median intake of flavonoids and
Table 1. Dietary surveys for adults included in the EFSA Comprehensive European Food Consumption Database.
Country Name of the dietary survey Survey period No of subjects Method Replicates
Belgium Diet National 2004 2004–5 1,304 24h recall 2
Czech Republic SISP04 2003–04 1,666 24h recall 2
Denmark Danish Dietary Survey 2000–02 2,822 Food record 7
Finland FINDIET 2007 2007 1,575 48h recall 1
France INCA2 2005–07 2,278 Food record 7
Germany National Nutrition Survey II 2005–07 10,419 24h recall 2
Hungary National Repr Surv 2003 1,074 Food record 3
Ireland NSIFCS 1997–99 958 Food record 7
Italy INRAN-SCAI 2005–06 2005–06 2,313 Food record 3
Latvia EFSA_TEST 2008 1,306 24h recall 2
Netherlands DNFCS-2003 2003 750 24h recall 2
Spain AESAN 1999–01 410 Food record 3
AESAN-FIAB 2009 981 24h recall 2
Sweden RIKSMATEN 1997–98 1997–98 1,210 Food record 7
UK NDNS 2000–01 1,724 Food record 7
See http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm2011 for details.
doi:10.1371/journal.pone.0128132.t001
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flavonoid sub-groups. Mean intake of total flavonoids, including oligomeric compounds, was
428 mg/d with the highest intake in the Central Region (506 mg/d), followed by the Northern
Region (348 mg/d) and the Southern Region (301 mg/d). The main types of flavonoids con-
sumed were thearubigins and theaflavins (168 mg/d), mainly from tea, and oligo- and polymer-
ic proanthocyanidins (124 mg/d), mainly from fruits and vegetable.
The highest intake of monomeric flavonoids was also found in the Central Region (157 mg/
d), followed by the Northern (124 mg/d) and Southern (95 mg/d) Region. The distribution of
intake was skewed for all compounds with a considerably lower median intake for all flavonoid
classes. The main type of monomeric compounds consumed were flavan-3-ols, of which 53
mg/d were gallated and 24 mg/d non-gallated compounds.
Regional variation
There were noticeable differences in flavonoid intake between different countries and Europe-
an regions (Fig 3). This was in particular pronounced for theaflavins and thearubigins where
mean intake in the Central Region (235 mg/d) was more than double than intake in the
Table 2. Names and synonyms of monomeric flavonoids used.
Compound Synonyms
Flavan-3-ols
(–)-epicatechin L-epicatechin, (–)-epicatechol, L-acacatechin
(–)-epigallocatechin gallocatechol, epigallocatechol,
(–)-epicatechin-3-gallate
(–)-epigallocatechin-
3-gallate
EGCG
(+)-catechin catechinic acid, catechuic acid, catergen, (+)-cianidanol, (+)-cyanidanol,
(+)-cyanidanol-3
(+)-gallocatechin gallocatechol
(+)-catechin-3-gallate
(+)-gallocatechin-3-gallate gallocatechol-gallate
Anthocyanidins
Cyanidin cyanidol, gastrotelos
Delphinidin delphinidol, ephdine
Malvidin
Pelargonidin pelargonidol
Peonidin
Petunidin petunidol
Flavones
Apigenin spigenin, versulin, apigenol
Luteolin luteolol, ﬂacitran, digitoﬂavone
Flavonols
Isorhamnetin isorhamnetol, 3'-methyl-quercetin
Quercetin sophoretin, meletin, xanthaurine, quercetol, quercetin, quertine, ﬂavin meletin
Myricetin cannabiscetin, myricetol
Kaempferol kaempferol, populnetin, rhamnolutein, robigenin, trifolitin, pelargidenolon,
rhamnolutin, swartziol
Flavanones
Hesperetin hesperitin, hesperin, 4'-methyl-cyanidanon
Naringenin
Eriodictyol
doi:10.1371/journal.pone.0128132.t002
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Fig 2. Main types and sources of flavonoids consumed by adults (18 to 64 years) in the European
Union.Data is based on mean flavonoid intake of all countries included in the survey.
doi:10.1371/journal.pone.0128132.g002
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Fig 3. Flavonoid intake of adults (18 to 64 years) in the European Union. The maps showmean flavonoid intake in mg/d per country, the pie charts the
relative contribution of different types of flavonoids.
doi:10.1371/journal.pone.0128132.g003
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Northern region (113 mg/d) and five times higher than in the Southern Region (44 mg/d).
Moreover, even in the Central Region we observed a wide range of intake, with low intakes in
the Czech Republic (43 mg/d) and Belgium (75 mg/d) and high intake in Ireland (505 mg/d),
the UK (352 mg/d) and the Netherlands (347 mg/d). Conversely, intake of proanthocyanidins
was highest in the Southern Region (161 mg/d) and similar in the Central (114 mg/d) and
Northern (111 mg/d) Region. For all other compound classes, intake was highest in the Central
Region, except for flavones and anthocyanidins, for which the highest intake was observed in
the Northern Region, in particular in Finland.
Flavonoid sources
Fig 2 shows a summary of the overall main contributors to total flavonoid intake and regional
data are shown in Tables 4 and 5. Non-alcoholic beverages, in particular tea, are the main
source of total and monomeric flavonoids in the European Union (mean: 66 mg/d) with no-
ticeable difference between countries and regions. In the Northern and Central region, flavo-
noids from non-alcoholic beverages are the main contributors, but in the Southern region the
main contributors are fruits and fruit products. Most other food sources contributed only little
to overall intake.
Whereas tea was the main contributor to dietary theaflavins and thearubigins, there was a
wider variety of sources for proanthocyanidins (Table 5, Fig 4). The main sources were fruits
(mean: 62 mg/d), in particular pome fruits (35 mg/d), berries and small fruits (11 mg/d) and
stone fruits (10 mg/d). There were however large variations between different countries (Fig 5):
in Finland and Latvia, berries and other small fruits were a major contributor to proanthocya-
nidins intake, whereas in the Southern Region, in particular in Italy and Spain, stone fruits
were an important source. In comparison to polymeric and monomeric flavan-3-ols, the con-
tribution from other groups were small and their main sources were fruits.
Individual compounds and sources
The contribution of different compounds to total flavonoid intake is summarised in Fig 2, and
shown by region in Table 6 and Fig 6. Thearubigins were the largest contributor to total flavo-
noid intake (156 mg/d) whereas theaflavins contributed only small amounts, and this can be
observed in all countries, independent of the total amount consumed. Conversely, the compo-
sition of proanthocyanidins is more variable. Overall, polymeric proanthocyanidins (DP> 10)
contribute most to total intake, but the contribution of different oligomers is very variable. Es-
pecially in countries of the Southern Region, intake of 4-6mers is much higher than in most
other countries (Fig 3).
Epigallocatechin-3-gallate (EGCG) is the main type of gallated compounds consumed (21
mg/d) and (–)-epicatechin the main non-gallated monomeric flavan-3-ol. The consumption of
all other types of flavonoids, except for quercetin (14 mg/d), was much lower.
Distribution of intake
The data available did not provide much information about the distribution of intake except
for median and mean values and these data allows only a limited assessment. The distribution
of intake was skewed for most compounds and countries, as median intake was always lower
than mean intake. This was in particular noticeable in Germany were mean monomeric flavo-
noid intake was more than 60-fold higher than median intake (181 mg/d vs 3 mg/d) and more
than 80-fold higher when including polymeric compounds (523 mg/d vs 7 mg/d). It was notice-
able that for some compounds, i.e. gallated flavan-3-ols, anthocyanidins, flavanones and fla-
vones as well as theaflavins and thearubigins, median intake in Germany was 0 mg/d. A
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similar, although less extreme, distribution was observed in Belgium (97 mg/d vs 3 mg/d for
monomeric flavonoids and 281 mg/d vs 8 mg/d for all flavonoids). Conversely, mean and me-
dian intake were very similar both in Ireland, both for monomeric compounds (249 mg/d vs
206 mg/d) and total flavonoids (851 mg/d vs 733 mg/d). The distribution of intake was most
skewed for flavanones, were median intake was 0 mg/d in most countries.
Fig 4. Contribution of different fruits to total proanthocyanidins.
doi:10.1371/journal.pone.0128132.g004
Fig 5. Relative contribution of individual compounds to total flavonoid intake.
doi:10.1371/journal.pone.0128132.g005
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Discussion
There has been extensive research on the beneficial and adverse health effects of flavonoids,
but there is only limited information on flavonoid intake in the general public. In this study,
we provide one of the most comprehensive analyses of flavonoid intake in Europe, based on
representative dietary surveys. The key strengths of this study are the data used, in particular
the European food consumption data [36] which provides representative dietary data, and the
detailed food composition data of the FLAVIOLA Flavanol Food Composition Database [35].
These data allow a reliable estimate of intake in the adult population. There are also some
methodological limitations which we have discussed in more detail previously [35]. The main
limitations were the resolution of data available and differences in the dietary assessment
Fig 6. Comparison of relative intake of individual flavonoids by region. The graph shows the ratio of average intake by region and average intake in
Europe.
doi:10.1371/journal.pone.0128132.g006
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methods between countries (Table 1), which is likely to have introduced bias. In particular dif-
ferences in assessment methods, such as differences in the number of days of assessment and
seasonality, will affect the results. In addition, all observational methods are prone to underre-
porting and it is therefore likely that the actual intake of flavonoids is higher than reported
here. Furthermore, the data available did not allow further statistical analyses.
More detailed data on the distribution of intake, or even the actual food consumption data
such as provided by the UK’s National Diet and Nutrition Survey (NDNS) or National Health
and Nutrition Examination Survey (NHANES) in the US, would have allowed a better explora-
tion of the data available. However, despite these limitations this study, in particular in combi-
nation with our previous research [35], provides the most detailed and accurate analysis of
flavonoid intake in the European Union.
Comparison with studies
There is a paucity of data on flavonoid intake in the general public and only few estimates exist.
Johannot and Somerset [47] reanalysed data from representative surveys in Denmark [48]
and the Netherlands [49, 50], but these estimates are considerably lower than estimated intake
in the current study and this might be due to a smaller number of food items for which data
were available. While there are only limited data from representative surveys, there are more
data available from other studies, such as clinical trials and observational cohorts, or food bal-
ance sheets. Beking and Vieira estimated flavonoid intake in the UK and Ireland using the lat-
ter approach [51], and their estimates are considerably higher for anthocyanidins (60 mg/d vs 9
mg/d for Ireland; 69 mg/d vs 16 mg/d for the UK) and flavanones (29 mg/d vs 8 mg/d for Ire-
land; 26 mg/d vs 9 mg/d for the UK), whereas their estimates for monomeric flavan-3-ols are
lower (190 mg/d vs 9 mg/d for Ireland; 140 mg/d vs 16 mg/d for the UK). Due to differences in
the methodologies used, it is difficult to explain the reason for these differences. Zamaro-Ros
et al. conducted one of the most detailed analysis of total flavonoid intake in the different cen-
tres of the European Prospective Investigation into Cancer (EPIC) study [34, 52–54]. These data
provided so far the most comprehensive analysis of flavonoid intake in Europe, but intakes
were considerably lower in our study: flavonol (30 mg/d vs 23 mg/d), flavanone (35 mg/d vs 14
mg/d), anthocyanidins (31 mg/d vs 19 mg/d) and proanthocyanidin (207 mg/d vs 124 mg/d)
intake were considerably higher than in our study. However, there are some important differ-
ences: Firstly, the participants of EPIC are not a representative selection of the general public
with some cohorts contributing only women or men and the cohorts consisting of mainly
healthy, middle-aged participants, and because of volunteer bias, participants are likely to have
more interest in diet and health and therefore a different diet. Secondly, intake assessment in
EPIC is based on dietary data collected in the 1990s, and it is likely that dietary habits
have changed.
Total intake of flavonoids in Europe is comparable with intake in Australia (454 mg/d), al-
though the consumption of anthocyanidins (3 mg/d in Australia vs 19 mg/d), flavanones (7
mg/d in Australia vs 14 mg/d) and flavones (0.5 mg/d in Australia vs 4 mg/d) was considerably
lower and it is mainly monomeric and polymeric flavan-3-ol that is higher (422 mg/d vs 370
mg/d; see [35] for a more detailed discussion) [47].
Based on data from NHANES, Bai et al. [55] estimated dietary intake of flavonoids in US
adults. Overall, intake in the US is similar to intake in Europe, although there are some notable
differences: intake of flavanones (22 mg/d vs 14 mg/d) is higher in the US population, but in-
take of flavones (4 mg/d vs 1 mg/d) and in particular anthocyanidins (9 mg/d vs 19 mg/d) is
considerably lower. Indeed, the intake of anthocyanidins is lower than in all European coun-
tries except for Ireland. It is more difficult to compare intake of flavan-3-ols or total flavonoids,
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as Bai et al. did not include thearubigins. However, it is noticeable that the intake of gallated
compounds is lower than intake in Europe (27 mg/d vs 53 mg/d) whereas the intakes of
(–)-epicatechin (68 mg/d vs 14 mg/d) and (+)-catechin (84 mg/d vs 10 mg/d) are much higher.
This is surprising as such a pattern of intake is difficult to explain as the main sources of
(–)-epicatechin and (+)-catechin also contain similar or higher amounts of gallated com-
pounds and thus it is not clear how such high intakes can be achieved.
Table 7 shows a comparison of mean and median intake data from Europe, Australia and
the USA, both from representative surveys and large cohort studies. While differences in meth-
odology and the definition of flavonoid subclasses, in particular polymeric compounds, make a
direct comparison difficult, the results are similar for most compounds. The most obvious dif-
ferences, which cannot be explained by methodological differences, are the lower intake of
anthocyanidins in the USA and Australia and the higher intake of flavanones in the USA.
Regional differences and distributions
There were large regional differences, both in the type of flavonoids consumed and the distri-
bution of intake. We have discussed differences in the consumption of flavan-3-ols, in particu-
lar gallated compounds and proanthocyanidins, in great detail previously [35], but there were
also noticeable differences for other compound classes. Intakes of anthocyanidins (in particular
cyanidin) and flavanones (in particular hesperetin) were highest in the Northern Region, in
particular in Finland. In Finland, the main source of anthocyanidins where berries and small
fruits (18 mg/d) whereas the main source of flavanones were citrus fruits (20 mg/d). Interest-
ingly, Finland had the highest intake of flavanones from citrus fruits in Europe, followed by
Italy (17 mg/d) and Sweden (11 mg/d). Within the Central Region, there was also a large vari-
ability of intake between countries. While overall flavonoid intake in Ireland was the highest in
Table 7. Mean andmedian flavonoid intake (in mg/d) in representative nutrition surveys and observational studies.
Country/
Region
Flavan-
3-ols
Anthocyanidins Flavonols Flavanones Flavones PA Thearubigins &
Theaﬂavins
Study Assessment
method¶
Mean intake
Europe† 77 19 23 14 4 124 168 Current study Table 1
Europe 76 31 29 5 35 198 107 EPIC§ [34, 52–54] 24HDR
USA† 182 9.2 18 22 1 98 — NHANES [55] 24HDR
USA 79 8 15 26 1 — — Nurses Health Study II
[56]
FFQ
Australia† — 2.9 21 7 1 — — Australian National
Nutrition Survey (NNS95)
[47]
24HDR
Median intake
Europe† 35 3 8 1 1 27 89 Current study Table 1
USA 20 <1 9 40 <1 175‡ — Iowa Women’s Health [12] FFQ
USA 17 10 13 17 1 132‡ — Cancer Prevention Study
II [13]
FFQ
For observational studies, mean or median intake is based on the mean/median intake of quintile 3.
†representative surveys;
‡includes monomeric compounds;
§non-weighed average of values;
¶FFQ: food frequency questionnaire, 24HDR 24h dietary recall
doi:10.1371/journal.pone.0128132.t007
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Europe, the intake of anthocyanidins was the lowest overall, and intake of flavanones was also
very low.
In this and previous studies [35], we have included France in the Southern Region as dietary
intake was more comparable with intake in Italy and Spain. However, there are some important
differences, and the intake of flavan-3-ols and anthocyanidins in France is considerably higher
than in the other countries of the Southern Region.
The distribution of intake is very skewed, with higher mean than median intake. This is in par-
ticular noticeable for compounds with high intake such as monomeric and polymeric flavan-3-ols
[35], but also for other compounds. The largest difference between mean and median intake was
observed in Germany where median intake for some flavan-3-ols, but also anthocyanidins, flava-
nones and flavones was 0 mg/d. Although regional differences in dietary intake might be an expla-
nation for this, as the Second German National Nutrition Survey [57] shows an almost two-fold
regional variation in the consumption of fruit, the main sources of monomeric flavonoids apart
from tea in Germany. However, data from EPIC Potsdam and EPIC Heidelberg show similar
mean intake of anthocyanidins (34 mg/d and 37 mg/d respectively) [52] and similar results are
also found for flavanones (44 mg/d and 36 mg/d) and flavones (7 mg/d and 8 mg/d).
Implications
The mean intake of flavonoids in Europe is lower than the amounts suspected to result in ad-
verse effects [24] and it is therefore unlikely that the habitual intake is detrimental to health.
However, the main focus of flavonoid research in the past decades has focused on their poten-
tially beneficial effect. Mean intake of most flavonoids in Europe is broadly comparable with
intake in observational studies conducted in the US [12–14, 56] and Europe [15, 23] benefits to
health are therefore likely to be limited. However, mean intake of anthocyanidins in some
countries (Finland, Latvia and France) was similar or higher than intake in the top quintile in
the Nurses Health Study II, where high anthocyanidins intake was associated with a reduced
risk of myocardial infarction [56]. It was also higher than in the UK twin study [58], where
high anthocyanin intake was associated with improved vascular function.
Results from observational studies are ambiguous and failed to show a clear association be-
tween flavonoid intake and health, especially for cardio-vascular diseases and all-cause mortali-
ty. Studies investigating these associations did not show significant trends suggestive of a dose-
response effect, and beneficial effects are mainly observed when comparing the quantiles with
lowest and very low intake [13, 15]. As this pattern is observed in several observational studies
with a very wide range of flavonoid intake [12, 13, 15, 56, 59, 60], it is unlikely that there is a
threshold effect. A similar pattern was observed for risk-factors of cardio-vascular diseases
[61]. Conversely, a statistically significant trend suggesting a dose response effect was observed
for associations with type 2 diabetes in Europe [23] and the US [62].
Previously, we have shown that flavan-3-ol intake in the general public is much lower than
the amounts used in most dietary intervention studies [33] and that it is unlikely that the
amount consumed has a direct impact on vascular health. While there are several systematic
reviews and meta-analyses for flavan-3-ols [33, 63, 64], there is a paucity of similar data for
other compounds. A recent review of dietary intervention studies with berry polyphenols
found that most intervention studies were conducted with anthocyanidin intakes in excess of
200 mg/d, which is much higher than the usual intake in Europe.
Conclusion
Our results provide a detailed overview of flavonoid consumption in European adults. These
results allow for a comparison of habitual intake in the general public with the amounts used in
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dietary intervention studies. Our data suggest that habitual intake of most compounds is likely
too low to result in a reduced risk of cardio-vascular diseases, but also too low to result in ad-
verse effects. However, a lack of systematic reviews and meta-analyses of intervention studies
makes these comparisons difficult. Further research is required to investigate the potential
health benefits of flavonoids, in particular the primary prevention of chronic diseases in the
general public. It is in particular important to use standardised and validated analytical meth-
ods and a consistent nomenclature of compounds to ensure that results are comparable. Fur-
thermore, the development of improved dietary assessment methods, especially using
nutritional biomarkers, is important to investigate the potential health effects of flavonoids in
larger observational studies.
An important result of our study was the skewed distribution of flavonoid intake, especially
in Belgium and Germany. In both countries, half of the adult population consumed only negli-
gible amounts of monomeric and polymeric flavonoids. Most observational studies conducted
so far have found the highest risk of cardio-vascular diseases with very low flavonoid intake
[12–14], and even though it is not clear whether this is due to dietary or other factors, it is im-
portant to investigate whether these dietary patterns have an impact on public health.
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